Futuro Clinical Trials LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$155,006	45
2024	Research	$7,860	7
2022	Research	$75,452	19
2021	Research	$43,477	9
2020	Research	$89,622	17
2019	Research	$152,077	25

Breakdown

Who paid Research payments · program years 2019–2025

Endo Pharmaceuticals Inc. $185,642 36 payments
Ipsen Innovation $138,891 23 payments
Organogenesis Inc. $93,525 13 payments
Regeneron Pharmaceuticals, Inc. $30,608 6 payments
Genentech, Inc. $26,931 9 payments
ConvaTec Inc. $19,600 1 payment
GlaxoSmithKline, LLC. $19,133 32 payments
Celgene Corporation $8,918 1 payment
Ge Healthcare $245 1 payment

Studies the money was for Research payments · program years 2019–2025

A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus $135,691 21 payments
Medical Xiaflex- Plantar Fibromatosis- POC - A Phase 1, Open-label, Randomized, Dose-ranging Study to Assess the Safety, Tolerability, and Pharmacokinetics of EN3835 in the Treatment of Plantar Fibromatosis $103,990 16 payments
PREPARE PuraPly AM/XT $87,525 12 payments
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis $53,160 9 payments
A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX) $30,608 6 payments
PH 1A B Sad Mad $26,931 9 payments
A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis $20,967 9 payments
Cnap Dfu (Wc-24-447) $19,600 1 payment
A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $19,133 32 payments
A phase 2 multicenter, randomized, doubleblind, placebo–controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (pda-002) in subjects who have diabetic foot ulcer with peripheral arterial disease (CCT-PDA-002-DFU-002) $8,918 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.